RELAPSED CANCER
Clinical trials for RELAPSED CANCER explained in plain language.
Never miss a new study
Get alerted when new RELAPSED CANCER trials appear
Sign up with your email to follow new studies for RELAPSED CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for recurrent glioblastoma: experimental drug LMP744 enters human trials
Disease control Recruiting nowThis study tests a new drug called LMP744 in people whose glioblastoma has come back after standard treatment. The drug is designed to kill cancer cells by blocking a key growth signal and interfering with DNA repair. Participants will receive the drug through a vein for 5 days e…
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether combining pembrolizumab (Keytruda) with bendamustine (Treanda) is safe and effective for people with Hodgkin lymphoma that has come back or is no longer responding to standard treatments. About 40 adults will receive the drug combination, and rese…
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New BTK-Degrader cocktail takes on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new oral drug called BGB-16673, which breaks down a protein that helps cancer cells grow, in combination with other cancer drugs. It is for people with B-cell cancers (like certain lymphomas) that have come back or stopped responding to treatment. The tria…
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo shows promise for hard-to-treat lymphoma
Disease control Recruiting nowThis study tests a combination of the immunotherapy drug epcoritamab with standard chemotherapy (GDP) in 32 adults whose large B-cell lymphoma has returned or not responded to treatment. The goal is to see if the combo can shrink tumors enough to allow for a stem cell transplant …
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: Dipenkumar Modi • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to tackle recurrent brain lymphomas
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of two drugs, zanubrutinib and pemetrexed, can safely control or shrink brain lymphomas that have come back or not responded to treatment. About 15 participants will receive the drugs in cycles, followed by maintenance therapy w…
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Triple-Drug cocktail targets Hard-to-Treat brain cancer
Disease control Recruiting nowThis study is testing a combination of three drugs—pembrolizumab, ibrutinib, and rituximab—in people whose primary central nervous system lymphoma has returned or not responded to treatment. The goal is to see if the combination can stop the cancer from growing for at least 6 mon…
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New Three-Drug cocktail aims to outsmart tough leukemia
Disease control Recruiting nowThis study tests a new combination of three drugs—roginolisib, venetoclax, and rituximab—in people with chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. The goal is to see if the combination is safe and can wipe out leukemia cells more e…
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New 4-Drug cocktail aims to control Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults whose multiple myeloma has returned or not responded to prior treatments. The main goal is to see how many patients respond to the therapy. This is not a …
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can multiple myeloma treatment move out of the hospital? new study tests Home-Based dosing
Disease control Recruiting nowThis study tests whether teclistamab, a drug for relapsed or refractory multiple myeloma, can be given safely outside the hospital. It involves 15 patients who have tried at least 3 prior treatments. The goal is to develop a clear process for outpatient care and measure how this …
Matched conditions: RELAPSED CANCER
Phase: PHASE4 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC